BofA analyst Farrell Granath raised the firm’s price target on Sabra Health Care (SBRA) to $23 from $22 and keeps a Buy rating on the shares. The firm updated estimates following the company’s Q4 report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA:
- Sabra Health Care price target raised to $21 from $20 at Cantor Fitzgerald
- Sabra Healthcare REIT Signals Confident 2026 Earnings Path
- Sabra Healthcare REIT: Solid SHOP Momentum Offset by Soft FFO Outlook and RCA Loan Uncertainty Supports Hold Rating
- Sabra Healthcare REIT Issues 2026 Outlook and Dividend
- Sabra Health Care sees FY26 FFO $1.55-$1.59, consensus $1.56